PT  - JOURNAL ARTICLE
AU  - Lyon, Gholson J.
AU  - Vedaie, Marall
AU  - Besheim, Travis
AU  - Park, Agnes
AU  - Marchi, Elaine
AU  - Gottlieb, Leah
AU  - Hsieh, Tzung-Chien
AU  - Klinkhammer, Hannah
AU  - Sandomirsky, Katherine
AU  - Cheng, Hanyin
AU  - Starr, Lois J.
AU  - Preddy, Isabelle
AU  - Tseng, Marcellus
AU  - Li, Quan
AU  - Hu, Yu
AU  - Wang, Kai
AU  - Carvalho, Ana
AU  - Martinez, Francisco
AU  - Caro-Llopis, Alfonso
AU  - Gavin, Maureen
AU  - Amble, Karen
AU  - Krawitz, Peter
AU  - Marmorstein, Ronen
AU  - Herr-Israel, Ellen
TI  - Expanding the Phenotypic spectrum of <em>NAA10</em>-related neurodevelopmental syndrome and <em>NAA15</em>-related neurodevelopmental syndrome
AID  - 10.1101/2022.08.22.22279061
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2022.08.22.22279061
4099  - http://medrxiv.org/content/early/2023/02/14/2022.08.22.22279061.short
4100  - http://medrxiv.org/content/early/2023/02/14/2022.08.22.22279061.full
AB  - Amino-terminal (Nt-) acetylation (NTA) is a common protein modification, affecting 80% of cytosolic proteins in humans. The human essential gene, NAA10, encodes for the enzyme NAA10, which is the catalytic subunit in the N-terminal acetyltransferase A (NatA) complex, also including the accessory protein, NAA15. The full spectrum of human genetic variation in this pathway is currently unknown. Here we reveal the genetic landscape of variation in NAA10 and NAA15 in humans. Through a genotype-first approach, one clinician interviewed the parents of 56 individuals with NAA10 variants and 19 individuals with NAA15 variants, which were added to all known cases (N=106 for NAA10 and N=66 for NAA15). Although there is clinical overlap between the two syndromes, functional assessment demonstrates that the overall level of functioning for the probands with NAA10 variants is significantly lower than the probands with NAA15 variants. The phenotypic spectrum includes variable levels of intellectual disability, delayed milestones, autism spectrum disorder, craniofacial dysmorphology, cardiac anomalies, seizures, and visual abnormalities (including cortical visual impairment and microphthalmia). One female with the p.Arg83Cys variant and one female with an NAA15 frameshift variant both have microphthalmia. The frameshift variants located toward the C-terminal end of NAA10 have much less impact on overall functioning, whereas the females with the p.Arg83Cys missense in NAA10 have substantial impairment. The overall data are consistent with a phenotypic spectrum for these alleles, involving multiple organ systems, thus revealing the widespread effect of alterations of the NTA pathway in humans.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work is supported by New York State Office for People with Developmental Disabilities (OPWDD) and NIH NIGMS R35-GM-133408. NIH grants R01 GM060293 and R35 GM118090 awarded to R.M. and T32 GM071339 grant awarded to L.G. also supported this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Both oral and written patient consent were obtained for research and publication, with approval of protocol #7659 for the Jervis Clinic by the New York State Psychiatric Institute - Columbia University Department of Psychiatry Institutional Review Board. Written family consent was given for publication of any photography of the children.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors. The sequencing data were generated as part of clinical testing, so the underlying raw data are not consented for deposition to a public database. https://humandiseasegenes.nl/naa10/ https://humandiseasegenes.nl/naa15/ https://db.gestaltmatcher.org/